Actuate Therapeutics - ACTU Operating profit EBITDA
The bet on the synergy between elite scientists and financial stability creates a powerful intellectual foundation for a breakthrough in oncology for Actuate Therapeutics, Inc. (ACTU). The distribution of EBITDA across periods confirms the current scale of operations, where a metric value of 0.00 captures the operating cash flow. Growth potential relies on the commercialization of eladrasib, although the development of the entire system is currently strictly limited by FDA regulatory requirements.
Actuate Therapeutics Inc (ACTU) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Actuate Therapeutics, Inc.|ACTU - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Actuate Therapeutics, Inc.|ACTU - Company Total Debt|Debt to Book Capital Actuate Therapeutics, Inc|ACTU - Company Long-Term Liabilities|Company Short-Term Debts Actuate Therapeutics|Quick Ratio actuatetherapeutics.com
- earnings and market ratios statistics:
ACTU - Net Income|Future Net Profit Actuate Therapeutics, Inc.|ACTU - P/E Multiple|Projected Price to Earnings Ratio Actuate Therapeutics, Inc|ACTU - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Actuate Therapeutics, Inc|ACTU - Operating profit before deduction of amortization|Earnings per share for the last four quarters Actuate Therapeutics|ACTU - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months actuatetherapeutics.com|ACTU - Earnings growth in current year|Expected net earnings per share growth next year Actuate Therapeutics, Inc.
- sales revenue and business income indicators:
Fundamental company valuation:Actuate Therapeutics ACTU
Absolute operating profit measures the cash flow from core operations before depreciation and taxes, determining the business's real efficiency in resource generation. By analyzing absolute EBITDA trends, an investor assesses capitalization stability, which for Actuate Therapeutics, Inc. (ACTU) is confirmed by the reliability of drug delivery logistics chains to research centers via specialized biomedical operators.
Competitor analysis for Actuate Therapeutics, Inc.
Operating profit EBITDA beigene.com ONC|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Corp - Income before deduction of interest, taxes and amortization|URGN (UroGen Pharma Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Therapeutics Inc. BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|ERAS - Profit before interest, taxes and amortization|Operating profit EBITDA DCTH (delcath.com)|Operating profit before depreciation charges Y-mAbs Corp|AURA - Profit before payment of interest, taxes and amortization|CADL (candeltx.com) - Operating profit before amortization|ARAY (accuray.com) - Operating profit before deduction of amortization|SELLAS Life Sciences Group Inc. (SLS) - Operating profit EBITDA|Operating profit before deduction of amortization CTOR|HURA: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Protara Therapeutics (TARA)|Company profit before taxes, interest and amortization FATE|Operating profit EBITDA WHWK (aadibio.com)|Company profit before taxes, interest and amortization TCRX (TScan)|CSBR - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization XBIT (XBiotech Inc)|cel-sci.com (CVM) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization OSTX (OS Therapies Incorporated)|Profit before payment of interest, taxes and amortization Radiopharm Theranostics Ltd|Profit before interest, taxes and amortization Artiva Biotherapeutics ARTV|Operating profit EBITDA ANL|VERU - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tempest Therapeutics TPST|xiliotx.com (XLO) - Profit before interest, taxes and amortization|RENB: Operating profit before deduction of amortization|Operating profit before depreciation charges Mural Oncology PLC (MURA)|KAPA (Kairos Pharma Inc) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization OnKure Therapeutics Inc (OKUR)|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Operating profit before deduction of amortization Curis, Inc. (CRIS)|Operating profit EBITDA APLM|Company profit before taxes, interest and amortization THAR|Operating profit EBITDA ADVB (advanbiomed.com)|GNPX - Operating profit before deduction of amortization|CLDI: Operating profit before deduction of amortization|SBFM - Operating profit EBITDA|Xenetic Biosciences (XBIO) - Profit before payment of interest, taxes and amortization|SLRX: Company profit before taxes, interest and amortization|PPBT (Purple Biotech Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization American Oncology Network, Inc. AONC|Operating profit EBITDA BGNE|Operating income before deduction of amortization Checkpoint Therapeutics|Elevation Oncology, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA iCAD, Inc. ICAD|Ikena Oncology, Inc. - Operating profit EBITDA|NTBL - Operating profit EBITDA|VIRX (Viracta Therapeutics) - Operating profit before deduction of amortization|MorphoSys AG - Income before deduction of interest, taxes and amortization|NAYA (NAYA Biosciences Corp) - Operating profit EBITDA|Operating profit EBITDA Ascentage Pharma Group International
